Mastic oil from Pistacia lentiscus var. chia inhibits growth and survival of human K562 leukemia cells and attenuates angiogenesis

Nutrition and Cancer

Volumn 55, Issue 1, 2006, Pages 86-93

  Loutrari, Heleni ^a   Magkouta, Sophia ^a   Pyriochou, Anastasia ^b   Koika, Vasiliki ^b   Kolisis, Fragiskos N ^c   Papapetropoulos, Andreas ^b   Roussos, Charis ^a  

^a UNIVERSITY OF ATHENS   (Greece)

^b UNIVERSITY OF PATRAS   (Greece)

^c NATIONAL TECHNICAL UNIVERSITY OF ATHENS   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ESSENTIAL OIL; FOOD ADDITIVE; MASTIC OIL; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PERILLYL ALCOHOL; PISTACIA LENTISCUS EXTRACT; PLANT EXTRACT; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANGIOGENESIS; ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CANCER PREVENTION; CELL PROLIFERATION; CELL STRAIN K 562; CELL SURVIVAL; CONCENTRATION RESPONSE; CONTROLLED STUDY; DIET SUPPLEMENTATION; DRUG MECHANISM; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LEUKEMIA CELL; MELANOMA B16; MOUSE; NONHUMAN; PISTACIA LENTISCUS; PROTEIN SECRETION; TIME;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BLOTTING, WESTERN; CELL DIVISION; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; K562 CELLS; MELANOMA, EXPERIMENTAL; MICE; MONOTERPENES; PISTACIA; PLANT OILS; TIME FACTORS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

PISTACIA LENTISCUS;

EID: 33749164989     PISSN: 01635581     EISSN: None     Source Type: Journal    
DOI: 10.1207/s15327914nc5501_11     Document Type: Article

References (43)

1. Milner JA: Strategies for cancer prevention: the role of diet. Br J Nutr 87, S265-S272, 2002.
2. Sabichi AL, Demierre MF, Hawk ET, Lerman CE, and Lippman SM: Frontiers in cancer prevention research. Cancer Res 63, 5649-5655, 2003.
3. Brenner DE and Gescher AJ: Cancer chemoprevention: lessons learned and future directions. Br J Cancer 93, 735-739, 2005.
4. Huwez FU, Thirlwell D, Cockayne A, and Ala'Aldeen DA: Mastic gum kills Helicobacter pylori. N Engl J Med 339, 1946, 1998.
5. Magiatis P, Melliou E, Skaltsounis AL, Chinou IB, and Mitaku S: Chemical composition and antimicrobial activity of the essential oils of Pistacia lentiscus var. chia. Planta Med 65, 749-752, 1999.
6. Marone P, Bono L, Leone E, Bona S, Carretto E, et al.: Bactericidal activity of Pistacia lentiscus mastic gum against Helicobacter pylori. J Chemother 13, 611-614, 2001.
7. Daifas DP, Smith JP, Blanchfield B, Sanders G, Austin JW, et al.: Effects of mastic resin and its essential oil on the growth of proteolytic Clostridium botulinum. Int J Food Microbiol 94, 313-322, 2004.
8. Andrikopoulos NK, Kaliora AC, Assimopoulou AN, and Papapeorgiou VP: Biological activity of some naturally occurring resins, gums and pigments against in vitro LDL oxidation. Phytother Res 17, 501-507, 2003.
9. Balan KV, Demetzos C, Prince J, Dimas K, Cladaras M, et al.: Induction of apoptosis in human colon cancer HCT116 cells treated with an extract of the plant product, Chios mastic gum. In Vivo 19, 93-102, 2005.
10. Papageorgiou V, Sagredos A, and Moser R: GLC-MS computer analysis of the essential oil of mastic gum. Chim Chronica New Ser 10, 119-124, 1981.
11. Wagner KH and Elmadfa I: Biological relevance of terpenoids. Overview focusing on mono-, di- and tetraterpenes. Ann Nutr Metab 47, 95-106, 2003.
12. Belanger JT: Perillyl alcohol: applications in oncology. Altern Med Rev 3, 448-457, 1998.
13. Crowell PL: Prevention and therapy of cancer by dietary monoterpenes. J Nutr 129, S775-S778, 1999.
14. Hudes GR, Szarka CE, Adams A, Ranganathan S, McCauley RA, et al.: Phase I pharmacokinetic trial of perillyl alcohol (NSC 641066) in patients with refractory solid malignancies. Clin Cancer Res 6, 3071-3080, 2000.
15. Stearns V, Coop A, Singh B, Gallagher A, Yamauchi H, et al.: A pilot surrogate end point biomarker trial of perillyl alcohol in breast neoplasia. Clin Cancer Res 10, 7583-7591, 2004.
16. Loutrari H, Hatziapostolou M, Skouridou V, Papadimitriou E, Roussos C, et al.: Perillyl alcohol is an angiogenesis inhibitor. J Pharmacol Exp Ther 311, 568-575, 2004.
17. Bergers G and Benjamin LE: Tumorigenesis and the angiogenic switch. Nat Rev Cancer 3, 401-410, 2003.
18. Moehler TM, Ho AD, Goldschmidt H, and Barlogie B: Angiogenesis in hematologic malignancies. Crit Rev Oncol Hematol 45, 227-244, 2003.
19. Molica S, Vacca A, Levato D, Merchionne F, and Ribatti D: Angiogenesis in acute and chronic lymphocytic leukemia. Leuk Res 28, 321-324, 2004.
20. Yancopoulos GD, Davis S, Gale NW, Rudge JS, Wiegand SJ, et al.: Vascular-specific growth factors and blood vessel formation. Nature 407, 242-248, 2000.
21. Ferrara N, Gerber HP, and LeCouter J: The biology of VEGF and its receptors. Nat Med 9, 669-676, 2003.
22. Bellamy WT, Richter L, Frutiger Y, and Grogan TM: Expression of vascular endothelial growth factor and its receptors in hematopoietic malignancies. Cancer Res 59, 728-733, 1999.
23. Dias S, Hattori K, Zhu Z, Heissig B, Choy M, et al.: Autocrine stimulation of VEGFR-2 activates human leukemia cell growth and migration. J Clin Invest 106, 511-521, 2000.
24. Liu RH: Potential synergy of phytochemicals in cancer prevention: mechanism of action. J Nutr 134, S3479-S3485, 2004.
25. Koutsoudaki C, Krsek M, and Rodger A: Chemical composition and antibacterial activity of the essential oil and the gum of Pistacia lentiscus Var. chia. J Agric Food Chem 53, 7681-7685, 2005.
26. Pipili-Synetos E, Papadimitriou E, and Maragoudakis ME: Evidence that platelets promote tube formation by EC on matrigel. Br J Pharmacol 125, 1252-1257, 1998.
27. Papadimitriou E, Polykratis A, Courty J, Koolwijk P, Heroult M, et al.: HARP induces angiogenesis in vivo and in vitro: implication of N or C terminal peptides. Biochem Biophys Res Commun 282, 306-313, 2001.
28. Ren XD, Kiosses WB, and Schwartz MA: Regulation of the small GTP-binding protein Rho by cell adhesion and the cytoskeleton. Embo J 18, 578-585, 1999.
29. Greenwald P: Clinical trials in cancer prevention: current results and perspectives for the future. J Nutr 134, S3507-S3512, 2004.
30. Giuliani N, Colla S, Lazzaretti M, Sala R, Roti G, et al.: Proangiogenic properties of human myeloma cells: production of angiopoietin-1 and its potential relationship to myeloma-induced angiogenesis. Blood 102, 638-645, 2003.
31. Rafii S, Mohle R, Shapiro F, Frey BM, and Moore MA: Regulation of hematopoiesis by microvascular endothelium. Leuk Lymphoma 27, 375-386, 1997.
32. Saaristo A, Karpanen T, and Alitalo K: Mechanisms of angiogenesis and their use in the inhibition of tumor growth and metastasis. Oncogene 19, 6122-6129, 2000.
33. Kang CD, Yoo SD, Hwang BW, Kim KW, Kim DW, et al.: The inhibition of ERK/MAPK not the activation of JNK/SAPK is primarily required to induce apoptosis in chronic myelogenous leukemia K562 cells. Leuk Res 24, 527-534, 2000.
34. Platanias LC: Map kinase signaling pathways and hematologic malignancies. Blood 101, 4667-4679, 2003.
35. Podar K, Tai YT, Davies FE, Lentzsch S, Sattler M, et al.: Vascular endothelial growth factor triggers signaling cascades mediating multiple myeloma cell growth and migration. Blood 98, 428-435, 2001.
36. Giuliani N, Lunghi P, Morandi F, Colla S, Bonomini S, et al.: Downmodulation of ERK protein kinase activity inhibits VEGF secretion by human myeloma cells and myeloma-induced angiogenesis. Leukemia 18, 628-635, 2004.
37. Hohl RJ and Lewis K: Differential effects of monoterpenes and lovastatin on RAS processing. J Biol Chem 270, 17508-17512, 1995.
38. Bishop AL and Hall A: Rho GTPases and their effector proteins. Biochem J 348, 241-255, 2000.
39. Fryer BH and Field J: Rho, Rac, Pak and angiogenesis: old roles and newly identified responsibilities in endothelial cells. Cancer Lett 229, 13-23, 2005.
40. Davis GE, Bayless KJ, and Mavila A: Molecular basis of endothelial cell morphogenesis in three-dimensional extracellular matrices. Anat Rec 268, 252-275, 2002.
41. Cascone I, Giraudo E, Caccavari F, Napione L, Bertotti E, et al.: Temporal and spatial modulation of Rho GTPases during in vitro formation of capillary vascular network. Adherens junctions and myosin light chain as targets of Rac1 and RhoA. J Biol Chem 278, 50702-50713, 2003.
42. Hoang MV, Whelan MC, and Senger DR: Rho activity critically and selectively regulates endothelial cell organization during angiogenesis. Proc Natl Acad Sci USA 101, 1874-1879, 2004.
43. Holstein SA and Hohl RJ: Monoterpene regulation of Ras and Ras-related protein expression. J Lipid Res 44, 1209-1215, 2003.